The Valley Desk

ArticleAdvances in therapyPublished

Real-World PSA Response and Overall Survival Among Men with mCSPC Receiving Apalutamide Versus Darolutamide (Both Without Docetaxel) in the US

Read the publication ↗ Open access copy ↗

Regional connection

Verified An author affiliation on the Europe PMC record names Johnson & Johnson. Affiliation source

Publication record

Type
Article
Venue
Advances in therapy
Published
Subject terms
Humans; Thiohydantoins; Pyrazoles; Pyrrolidines; Prostate-Specific Antigen; Retrospective Studies; Aged; Aged, 80 and over; Middle Aged; United States; Male; Prostatic Neoplasms, Castration-Resistant
PubMed ID
42518140
PubMed Central ID
PMC13619676
Open access
Yes, open
Added to directory
Source checked

Report a correction or request removal